Definium Therapeutics Inc

AtaiBeckley (ATAI) shares surged 15.6% as FDA staffing guidance for psychedelic trials boosted BPL-003's two-hour clinic model, potentially reducing monitoring costs vs. longer treatments.

DFTX shares soared 64.2% premarket after Definium's Phase 3 Emerge trial showed DT120 achieved an 8.1-point placebo-adjusted benefit in major depressive disorder.

Definium Therapeutics advanced after Stifel and Piper Sandler issued Buy ratings, spotlighting its LSD-based drug DT120 in late-stage trials for anxiety and depression. The company will host an investor day on April 22 to discuss upcoming Phase 3 data expected through 2026.